Substance Spotlight: Dissociatives — the ketamine clinic boom is meeting its first wave of regulatory pressure

For five years, ketamine has been the fastest-growing legitimate intervention in mental health and the fastest-growing gray-market intervention at the same time. The two phenomena overlap and are not the same thing. The 2026 question is no longer “does ketamine work for treatment-resistant depression” — there is real evidence it does. The 2026 question is which version, prescribed by whom, at what setting, with what monitoring. PharmExec’s recent industry analysis frames this clearly: the field is meeting its first regulatory reckoning.

The treatment lens — three increasingly different products

The cleanest way to think about ketamine in 2026 is not as one drug but as three different products with three different regulatory and safety profiles. Spravato (esketamine), nasal spray — FDA-approved in 2019 for treatment-resistant depression, administered only under a Risk Evaluation and Mitigation Strategy (REMS) program, requiring two hours of post-dose in-clinic monitoring, insurance-covered on most commercial plans after prior authorization. Off-label IV ketamine clinics — racemic ketamine, infused over 40 minutes to an hour in a clinic, monitored on-site, almost always cash-pay, $700–$1,200 per session, no FDA approval for psychiatric indications. At-home compounded ketamine — telehealth-prescribed lozenges or troches, taken at home with no in-person monitoring, the fastest-growing and most regulatorily exposed segment of the field. The dissociation profile differs across these, with comparative data suggesting roughly 58% dissociation incidence on IV racemic vs. 34% on intranasal esketamine.

The harm-reduction lens — what enforcement is starting to look like

The FDA’s enforcement focus has shifted onto the at-home compounded segment, where deaths and serious injuries during unmonitored use have prompted direct safety warnings from clinical providers. The argument for at-home access — that it democratizes a high-cost intervention — is not wrong. The argument against — that you cannot monitor for laryngospasm, cardiovascular events, or dissociation-related injury when no one is watching — is also not wrong. The likely 2026–2027 arc is tighter prescribing rules for compounded ketamine, more REMS-style requirements, and continued expansion of Spravato as the insurance-covered, monitored standard of care.

The policy lens — what this maps to for SUD recovery

Ketamine matters for SUD recovery for two reasons that are still contested. First, there is real but early evidence on ketamine for alcohol use disorder and for cocaine use disorder when paired with motivational therapy. Second, there is a community of people who use ketamine non-medically, including in club and party contexts, where harm-reduction conversations now have to engage with the fact that “ketamine is a treatment” and “ketamine is a recreationally used substance” are both simultaneously true. The honest version: ketamine has therapeutic value in supervised, indication-appropriate contexts, and the same compound used outside those contexts carries real risks, including bladder injury (ulcerative cystitis) at high recreational doses.

Where the field disagrees

Reasonable clinicians disagree on whether at-home compounded ketamine should exist as a category at all. Reasonable patient advocates argue that requiring two-hour in-clinic monitoring for every dose is a wealth filter. Reasonable regulators are trying to write rules that distinguish “monitored telehealth with pharmacy controls” from “unmonitored cash-pay scripts,” and the line is genuinely hard to draw. The next 12 months will produce both tighter rules and more product — that is what regulatory reckonings tend to look like.

Resources

If you are considering ketamine therapy for depression, ask whether the program is offering Spravato (FDA-approved, REMS-monitored), an in-clinic IV ketamine program (off-label, monitored), or at-home compounded ketamine (no FDA approval). The answer should be straightforward, and your provider should be able to explain the safety differences without defensiveness. See Rize’s dissociatives resources for a broader frame.

If you or someone you love is in crisis, call or text 988 (the Suicide and Crisis Lifeline). If a person is unresponsive after taking a substance, call 911 immediately.

If you or someone you love is in crisis, call or text 988 (the Suicide and Crisis Lifeline).